Xevinapant
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Xevinapant
- Molecular weight
- 561.73
- Structure (SMILES)
- CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)CC[C@H]2CC[C@@H](C(=O)NC(c3ccccc3)c3ccccc3)N2C1=O
- at 406
- At-406
- d 1143
- D-1143
- debio 1143
- Debio 1143
- Debio 1143 (AT-406)
- DEBIO-1143
- iap inhibitor at 406
- IAP INHIBITOR AT-406
- msc2735845a
- MSC2735845A
- sm 406
- SM-406
- xevinapant
- Xevinapant
- Xevinapant (Debio 1143)
- xevinapant [INN]
- XEVINAPANT [USAN]
- Xevinapant [WHO-DD]
- Xevinapant 200 mg (Oral Solution)
- xevinapant inn
- xevinapant usan
- xevinapant who dd
- CAS registry numbers
- 1071992-99-8
- ChEMBL ID
- CHEMBL2158051
- InChIKey
- LSXUTRRVVSPWDZ-MKKUMYSQSA-N
- PubChem compound IDs
- 25022340
- FDA ingredient codes (UNII)
- N65WC8PXDD
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- xevinapant
- Type
- Synthetic organic
- Drug name stem
- -napant; -vin-
- Action
- Antagonist
- Action type
- Antagonist
- Target
- X-linked inhibitor of apoptosis
- Gene symbol
- XIAP
- Protein identifier
- P98170
- Median affinity
- 7.18
- Affinity units
- pKi
- Action
- Antagonist
- Action type
- Antagonist
- Target
- baculoviral IAP repeat containing 3
- Gene symbol
- BIRC3
- Protein identifier
- Q13489
- Median affinity
- 8.29
- Affinity units
- pKi
- Action
- Antagonist
- Action type
- Antagonist
- Target
- baculoviral IAP repeat containing 2
- Gene symbol
- BIRC2
- Protein identifier
- Q13490
- Median affinity
- 8.72
- Affinity units
- pKi
- Primary target
- Yes
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0006859
- Subject identifier
- D006258
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Glioma
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0100342
- Subject identifier
- D005910
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000222
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000574
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0006859
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005062
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005140
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005494
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005627
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008433
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0010150
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0011962
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0015667
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0015686
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018364
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018874
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0100342
- Highest recorded phase
- 1
- NCT01078649
- NCT01930292
- NCT04122625
- NCT01265199
- NCT02022098
- NCT04459715
- NCT05724602
- NCT05930938
- NCT03270176
- NCT05386550
- NCT06056310
- NCT06463184
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 3
- Polar surface area
- 110.85
- Calculated partition coefficient (ALogP)
- 2.62
- Calculated partition coefficient (XLogP)
- 3.1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 9
- Heavy atoms
- 41
- Molecular formula
- C32H43N5O4
- Monoisotopic mass
- 561.33150487
- Natural product
- No
- Recorded assays
- 543
- Active assays
- 88
- Confirmatory
- Other
Oral bioavailability
- Median
- 38
- Mean
- 38.3333
- Minimum
- 31
- Maximum
- 46
- Unit
- %
- Assays
- 3
- Standard deviation
- 7.50555
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (53)
- A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold Symptoms
- A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
- A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection
- A Pharmacokinetic Study of PLENVU® in Healthy Subjects
- A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers
- A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462
- A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 474121, and Whether it Makes a Difference if BI 474121 is Taken as a Tablet or a Drink.
- A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144
- A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
- A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004
- A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants
- A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males
- A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP
- A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression
- A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy Subjects
- A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants
- Bioavailability Study of Magne-B6 New Formulation
- Clinical Study for Development of Oral Galactose Single Point (OGSP) Solution (G.S.P. Oral Solution®)
- Comparative Bioavailability of Dexketoprofen Trometamol Oral Solution vs Tablet Formulations
In development for (9)
- Acute myeloid leukemia Phase 1
- Acute myeloid leukemia by FAB classification Phase 1
- Cancer Phase 1
- Head and neck cancer Phase 3
- Head and neck squamous cell carcinoma Phase 3
- Lymphoma Phase 1
- Malignant glioma Phase 1
- Neoplasm Phase 1
- Non-small cell lung carcinoma Phase 1